Cambi ASA (CAMBI)
Oslo Børs · Norway · prices in NOK · close of 27 Oct 2026
Key indicators
| Last close | NOK 23.50 |
|---|---|
| 52-week range | 15.00 – 24.70 |
| Return, 1 month / 3 months | −4.1% / +8.3% |
| Return, 1 year / 3 years | +25.6% / +105.3% |
| Trend | Uptrend |
| RSI (14) | 54 |
| Volatility (1 year) | 38.0% |
| Worst drawdown (1 year) | -21.3% |
| Average daily value traded | 1.11M NOK |
| Dividend yield | 3.2% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Cambi ASA supplies thermal hydrolysis technology for wastewater treatment. Its systems treat sewage sludge at treatment plants, breaking the material down before digestion so that utilities can handle larger volumes and recover resources from the waste. The company provides the process equipment along with related engineering and support services. Cambi is based in Norway and works with water utilities and municipal treatment operators in several countries, serving customers who manage sludge from household and industrial wastewater.
The shares are listed on the Oslo Børs in Norway under the code CAMBI, and the price on this page is in Norwegian kroner (NOK). Our dividend records, which start in 2019, show payments in 4 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Cambi ASA (CAMBI) trades on the Oslo Børs in Norway. It last closed at NOK 23.50 on 27 October 2026.
Its price-based Market X-Ray is 63 out of 100 (a fair price profile), ranking 94 of 294 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 25.6% and over the last three months it rose 8.3%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Oslo Børs
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 85 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 14.2% | ||
| From 52-week high | -4.1% | ||
| Momentum | 76 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 8.3% | ||
| 6-month return | 22.2% | ||
| 12-month return, skipping the last month | 30.9% | ||
| Stability (higher is calmer) | 56 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 38.0% | ||
| Worst drawdown, 1 year (smaller is calmer) | -21.3% | ||
| Liquidity | 43 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 1.11M NOK | ||
| Zero-volume days | 0.0% | ||
| Income | 27 · Weak | Dividend is small or irregular. | |
| Dividend yield | 3.2% | ||
| Years with dividends | 4 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
Weak spots
- Liquidity: Thinly traded: prices can jump and exits can be hard.
- Income: Dividend is small or irregular.
Returns
| 1 week | +1.3% |
|---|---|
| 1 month | −4.1% |
| 3 months | +8.3% |
| 6 months | +22.2% |
| 1 year | +25.6% |
| 3 years | +105.3% |
| 5 years | +177.1% |
Signals
| 50-day / 200-day average | 23.17 / 20.58 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 1.02 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 11 May 2026 | NOK 0.3000 |
| 10 Nov 2025 | NOK 0.4500 |
| 12 May 2025 | NOK 0.3000 |
| 3 May 2024 | NOK 1.0000 |
| 2 Oct 2023 | NOK 0.6000 |
| 11 May 2023 | NOK 0.1500 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Oslo Børs; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.